"Consumers and health care professionals will soon find updated labeling for extended-release and long-acting opioid pain relievers to help ensure their safe and appropriate use.
In addition to requiring new labeling on these prescript"...
- Patient Information:
Details with Side Effects
During clinical trials of RELISTOR administered subcutaneously, no cases of methylnaltrexone bromide overdose were reported. A study of healthy volunteers noted orthostatic hypotension associated with a dose of 0.64 mg/kg administered as an intravenous bolus.
Signs or symptoms of orthostatic hypotension should be monitored, and treatment should be initiated, as appropriate.
RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Last reviewed on RxList: 9/19/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Relistor Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.